Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma
Cellular Oncology · 2024-08 · 47 (4) · 1277-1294
DOI: 10.1007/s13402-024-00927-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 23.02.2024. Verfasst von Tingyu Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Sunitinib, Carcinoma, Renal Cell, Autophagy, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, The Enterprise United Foundation of Guangdong Province.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
- Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China. yuex5@mail.sysu.edu.cn.
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. hanhui@sysucc.org.cn.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. liury@sysucc.org.cn.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- The Enterprise United Foundation of Guangdong Province
Zitieren
APA
Liu, T., Yue, X., Chen, X., Yan, R., Wu, C., Li, Y., Bu, X., Han, H., & Liu, R. Y. (2024). Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma. Cellular Oncology, 47(4), 1277-1294. https://doi.org/10.1007/s13402-024-00927-9
Vancouver
Liu T, Yue X, Chen X, Yan R, Wu C, Li Y, et al. Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma. Cellular Oncology. 2024;47(4):1277-1294. doi:10.1007/s13402-024-00927-9
BibTeX
@article{Liu2024,
author = {Liu, Tingyu and Yue, Xin and Chen, Xue and Yan, Ru and Wu, Chong and Li, Yunzhi and Bu, Xianzhang and Han, Hui and Liu, Ran-Yi},
title = {Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma},
journal = {Cellular Oncology},
year = {2024},
volume = {47},
number = {4},
pages = {1277--1294},
doi = {10.1007/s13402-024-00927-9}
}
EUVIMED